HC Wainwright Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price

AnaptysBio (NASDAQ:ANAB) had its price target increased by HC Wainwright from $38.00 to $59.00 in a report released on Tuesday, MarketBeat reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for AnaptysBio’s Q3 2025 earnings at ($1.59) EPS, Q4 2025 earnings at ($1.62) EPS, FY2025 earnings at ($5.82) EPS, FY2026 earnings at ($6.35) EPS, FY2027 earnings at ($11.93) EPS, FY2028 earnings at ($3.94) EPS and FY2029 earnings at ($1.88) EPS.

A number of other research analysts also recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. UBS Group reaffirmed a “neutral” rating and issued a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. Finally, Wedbush reissued an “outperform” rating and set a $45.00 price objective on shares of AnaptysBio in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.75.

AnaptysBio Price Performance

NASDAQ ANAB opened at $31.34 on Tuesday. The stock has a market capitalization of $877.52 million, a P/E ratio of -7.00 and a beta of -0.18. The business has a 50 day simple moving average of $22.34 and a 200 day simple moving average of $21.74. AnaptysBio has a one year low of $12.21 and a one year high of $36.54.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.16. The firm had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. Equities analysts expect that AnaptysBio will post -6.08 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC increased its position in shares of AnaptysBio by 433.3% during the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock worth $86,139,000 after acquiring an additional 3,764,720 shares in the last quarter. Palo Alto Investors LP boosted its stake in AnaptysBio by 20.9% during the 1st quarter. Palo Alto Investors LP now owns 1,020,713 shares of the biotechnology company’s stock valued at $18,975,000 after purchasing an additional 176,742 shares during the last quarter. Woodline Partners LP increased its holdings in AnaptysBio by 63.1% during the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after purchasing an additional 305,950 shares in the last quarter. 683 Capital Management LLC raised its stake in shares of AnaptysBio by 155.6% in the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after purchasing an additional 304,373 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of AnaptysBio by 21.5% in the first quarter. Victory Capital Management Inc. now owns 406,430 shares of the biotechnology company’s stock valued at $7,556,000 after purchasing an additional 71,980 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.